Phase 1 Prostatic Neoplasms Clinical Trials
13 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–13 of 13 trials
Recruiting
Phase 1Phase 2
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
Prostate CancerNeoplasmsNeoplasms by Site+7 more
Pathos AI, Inc.252 enrolled18 locationsNCT06785636
Recruiting
Phase 1Phase 2
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
Prostatic Neoplasms, Castration-Resistant
Merck Sharp & Dohme LLC220 enrolled77 locationsNCT06353386
Recruiting
Phase 1
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
Prostatic Neoplasms
Janssen Research & Development, LLC140 enrolled6 locationsNCT07082920
Recruiting
Phase 1
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
Prostatic Neoplasms
Janssen Research & Development, LLC40 enrolled5 locationsNCT07319871
Recruiting
Phase 1Phase 2
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
Prostate CancerMetastatic Castration-resistant Prostate CancerUrogenital Neoplasms+3 more
Blue Earth Therapeutics Ltd82 enrolled23 locationsNCT05413850
Recruiting
Phase 1Phase 2
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
Prostate CancermCRPC (Metastatic Castration-resistant Prostate Cancer)Prostatic Neoplasms, Castration-Resistant+3 more
Celcuity Inc54 enrolled13 locationsNCT06190899
Recruiting
Phase 1Phase 2
64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
Prostatic Neoplasms, Castration-Resistant
Clarity Pharmaceuticals Ltd54 enrolled7 locationsNCT04868604
Recruiting
Phase 1
A Study of DM002 in Patients With Advanced Solid Tumors
Ovarian NeoplasmsColorectal NeoplasmsEndometrial Neoplasms+2 more
Xadcera Biopharmaceutical (Suzhou) Co., Ltd.160 enrolled5 locationsNCT06751329
Recruiting
Phase 1
Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer
Prostatic Neoplasms, Castration-Resistant
Weill Medical College of Cornell University30 enrolled1 locationNCT05743621
Recruiting
Phase 1Phase 2
HTL0039732 in Participants With Advanced Solid Tumours
SarcomaUrinary Bladder NeoplasmsUterine Cervical Neoplasms+11 more
Cancer Research UK150 enrolled5 locationsNCT05944237
Recruiting
Phase 1Phase 2
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Endometrial CancerAdvanced Solid TumorDiffuse Large B Cell Lymphoma+5 more
Novartis Pharmaceuticals275 enrolled60 locationsNCT04104776
Recruiting
Phase 1
Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer
Prostatic Neoplasms, Castration-Resistant
Endocyte99 enrolled2 locationsNCT04597411
Recruiting
Phase 1Phase 2
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
Prostatic Neoplasms
The Methodist Hospital Research Institute25 enrolled1 locationNCT01913106